1-2 of 2
Dawn Kettner
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase I Study of Bortezomib, (BTZ) Followed by High-Dose Melphalan, (HD Mel) and BTZ as Conditioning Regimen for Tandem Peripheral Blood Stem Cell Transplants (TanPSCT) in Patients with Primary Refractory Multiple Myeloma (MM) and Plasma Cell Leukemia (PCL).

Free
Todd Alekshun, MD, Christine Mcisaac-Simonelli, RN, Mohamed Kharfan-Dabaja, MD, William Dalton, MD, PhD, Benjamin Djulbegovic, MD, Hugo Fernandez, MD, Daniel M. Sullivan, MD, Ernesto Ayala, MD, Teresa L. Field, MD, Dawn Garrett, LPN, William E. Janssen, PhD, Beth Maddox, RN, Lia Perez, MD, Dawn Kettner, PA, Janelle Perkins, PharmD, Jyoti Raychaudhuri, MD, Claudio Anasetii, MD, Melissa Alsina, MD
Journal: Blood
Blood (2007) 110 (11): 5131.
https://doi.org/10.1182/blood.V110.11.5131.5131
Published: 2007
Journal Articles

Safety and Activity of KOS-953 in Patients with Relapsed Refractory Multiple Myeloma (MM): Interim Results of a Phase 1 Trial.

Free
Paul G. Richardson, MD, Asher A. Chanan-Khan, MD, Melissa Alsina, MD, Deborah Doss, R.N., Beverly Landrigan, R.N., Dawn Kettner, N.P., Maher Albitar, MD, Constantine Mitsiades, MD, Gillian F. Cropp, MS, Robert G. Johnson, MD, Alison L. Hannah, MD, Kenneth C. Anderson, MD
Journal: Blood
Blood (2005) 106 (11): 361.
https://doi.org/10.1182/blood.V106.11.361.361
Published: 2005